Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Deals

GenScript Biotech’s ProBio Subsidiary Receives USD 37.25M Investment from Zhenjiang Gaoxin

Fineline Cube Jul 4, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that Zhenjiang Gaoxin...

Company Deals

Zhiyi Bio Raises RMB 100M in Series B++ Round for LBP Pipeline Development

Fineline Cube Jul 4, 2022

China-based leading live biotherapeutics (LBP) company Guangzhou Zhiyi Biotechnology Co., Ltd has recently raised RMB...

Company Deals Drug

Brii Biosciences Exercises Option for VIR-3434 in Greater China

Fineline Cube Jul 4, 2022

China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive...

Company Drug

Innovent Biologics Doses First Patient in IBI112 Phase II Study for Ulcerative Colitis

Fineline Cube Jul 4, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) announced the successful first patient dosing in a Phase...

Company Deals

VivaVision Biotech and Dragon Sail Pharmaceutical Partner on Ophthalmology R & D

Fineline Cube Jul 4, 2022

China’s VivaVision Biotech Inc. has entered into a partnership with compatriot firm Dragon Sail Pharmaceutical....

Company Drug

Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study

Fineline Cube Jul 4, 2022

China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...

Company Drug

InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production

Fineline Cube Jul 4, 2022

Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in...

Company Drug

Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention

Fineline Cube Jul 4, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval...

Company

Medtronic Kanghui and Changzhou High-Tech Zone Partner on Science Park

Fineline Cube Jul 4, 2022

Medtronic Kanghui and Changzhou National High-Tech Industrial Development Zone have agreed to collaborate on the...

Policy / Regulatory

NHC Releases Technical Guidelines for Drug Clinical Evaluation

Fineline Cube Jul 4, 2022

The National Health Commission (NHC) has released the “Technical Guidelines for Comprehensive Clinical Evaluation of...

Company Deals

HitGen and Haichang Bio Partner to Develop Anti-Cancer RNAi Drugs

Fineline Cube Jul 4, 2022

China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...

Policy / Regulatory

Hainan Medical Products Administration Issues Guidelines for Imported Drug Management

Fineline Cube Jul 4, 2022

The Hainan Medical Products Administration (HMPA) has released a set of guidelines that took effect...

Company Drug

Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors

Fineline Cube Jul 4, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...

Company Drug

Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide

Fineline Cube Jul 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...

Company Deals

Fosun Pharmaceutical and ReNeuron Renew CTX Cell Therapy Deal for China

Fineline Cube Jul 4, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has negotiated a new...

Company

Eurofins DiscoverX Opens Shanghai Office to Expand Asia-Pacific Operations

Fineline Cube Jul 4, 2022

California-based Eurofins DiscoverX Products LLC, a manufacturer of drug discovery solutions, announced the opening of...

Company Deals

Solasia Pharma Reduces China Operations, Transfers Drug Rights to Lee’s

Fineline Cube Jul 4, 2022

Japan-based Solasia Pharma KK (TYO: 4597) announced that it will reduce its direct operations in...

Policy / Regulatory

NMPA Releases Plans to Support HK and Macau Drug, Device Production in Mainland Cities

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released two implementation plans aimed at supporting Hong...

Company Drug

Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials

Fineline Cube Jul 1, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical...

Company Drug

Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC

Fineline Cube Jul 1, 2022

The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...

Posts pagination

1 … 632 633 634 … 643

Recent updates

  • Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline
  • NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines
  • Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib
  • NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications
  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Company

Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib

Policy / Regulatory

NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.